Company intelligence / Profile preview

OncoVerity

Aurora, Colorado, United States

Ownership: Private
Development stage: Phase 1

Overview

OncoVerity is developing cusatuzumab, a first-in-class anti-CD70 antibody that has shown promising results in early AML studies. The company uses computational biology and single-cell analysis to identify patients most likely to benefit from treatment.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

cusatuzumab

Partnerships

argenxUCHealthUniversity of Colorado Anschutz Medical Campus

Beyond the preview

Go deeper on OncoVerity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoVerity.

Explore the full profile